Abstract: OBJECTIVE To evaluate the clinical efficacy and safety of teicoplanin in treatment of type 2 diabetes mellitus patients complicated with community-acquired pneumonia (CAP) caused by gram-positive cocci. METHODS By means of retrospective study, the type 2 diabetes mellitus patients complicated with CAP who were hospitalized from 2014 to 2017 were observed, totally 72 patients who were diagnosed and highly suspected with gram-positive cocci pneumonia and were treated with teicoplanin were recruited as the study objects and divided into the positive sputum culture group and the negative sputum culture group according to the result of sputum culture. The clinical curative effect, bacterial clearance rate and incidence of adverse reactions were observed. RESULTS The treatment course of teicoplanin of the 72 patients varied from 8 to 14 days, the total effective rate of clinical treatment was 88.89%. There was no significant difference in the total effective rate between the positive sputum culture group and the negative sputum culture group,the negative rate of bacteria of the positive sputum culture group was 87.75%. Among the 72 patients,The blood glucose and the infection in 69.40% of the patients were effectively under control. The incidence of adverse reactions was 6.94% among the 72 patients. CONCLUSION Teicoplanin can achieve remarkable effect on treatment of type 2 diabetes mellitus patients complicated with CAP caused by gram-positive cocci, and the incidence of adverse reactions is low.